Scinai Immunotherapeutics Ltd. filed a Form 6-K on November 17, 2026, announcing an ADS ratio change effective November 19, 2026, that will alter the number of ordinary shares each American Depositary Share represents from 40,000 to 160,000.

Key Highlights

  • New ADS ratio: Effective November 19, 2026, one ADS will represent 160,000 ordinary shares, up from 40,000 ordinary shares.
  • Equivalent effect: According to the filing, the change will have the same effect as a one-for-four reverse split of the ADSs.
  • Trading symbol unchanged: The ADSs are expected to begin trading on an adjusted basis on the Nasdaq Capital Market under the symbol "SCNI" at the opening of trading on November 19, 2026.
  • New CUSIP: The filing states the new CUSIP number for the ADSs will be 09073Q501.
  • Compliance objective: The company disclosed the change is intended to increase the per-ADS trading price and regain compliance with Nasdaq Listing Rule 5550(a)(2), which requires a minimum bid price of $1.00 per ADS.
  • Fractional ADS handling: No fractional new ADSs will be issued; the depositary bank will attempt to sell fractional entitlements and distribute net cash proceeds to applicable ADS holders.

Scinai Immunotherapeutics Changes ADS-to-Share Ratio to Address Minimum Bid Requirement

Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI), a biopharmaceutical company based in Jerusalem, Israel, announced the ADS ratio change via a Form 6-K report submitted to the U.S. Securities and Exchange Commission on November 17, 2026. Under the revised ratio, one ADS will represent 160,000 ordinary shares, compared with the prior ratio of one ADS representing 40,000 ordinary shares, according to the filing.

The company disclosed that no action is required by ADS holders to give effect to the change. Where a holder's existing ADS position would otherwise result in a fractional entitlement, the filing states that such fractional entitlements will be aggregated and the depositary bank will attempt to sell them, with net cash proceeds distributed to the applicable holders. The filing does not specify a timeline for that distribution.

The company stated it is implementing the ADS Ratio Change "with the objective of increasing the per-ADS trading price and regaining compliance with Nasdaq Listing Rule 5550(a)(2)," which requires a minimum bid price of $1.00 per ADS for continued listing on the Nasdaq Capital Market. The filing includes the cautionary statement that "there can be no assurance that the ADS Ratio Change will enable the Company to regain or maintain compliance with Nasdaq's continued-listing requirements." The Form 6-K was signed by Chief Executive Officer Amir Reichman.

What Was Disclosed

Scinai Immunotherapeutics disclosed an ADS ratio change from 1:40,000 to 1:160,000 ordinary shares, effective November 19, 2026, equivalent to a one-for-four reverse ADS split, undertaken to pursue compliance with Nasdaq's minimum bid price rule.